

PRESS RELEASE

BSE: 506690	NSE: UNICHEMLAB	Reuters: UNLB.BO	Bloomberg: UN@IN

Mumbai, October 26, 2012

<u>Unichem Laboratories receives ANDA tentative approval from USFDA for Memantine Hydrochloride</u> <u>Tablets</u>

Unichem laboratories Limited are pleased to announce that it has received ANDA tentative approval from the United States Food and Drug Administration (U.S. FDA) for *Memantine Hydrochloride Tablets*. Final approval will be received after the patent expires on April 11, 2015.

Memantine Hydrochloride Tablets 5mg and 10mg are therapeutically equivalent to NAMENDA[®] Tablets 5mg and 10mg of Forest Laboratories Inc.,

Memantine Hydrochloride is used to treat moderate to severe dementia of the Alzheimer's type. Further, it reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease.

The product will be commercialized from Unichem's GOA plant. Active pharmaceutical ingredient i.e. *Memantine Hydrochloride* used for this ANDA is also made in house at Pithampur plant.

The market size is US\$ 1.5 billion as of March, 2012 at brand price.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at <u>www.unichemlabs.com</u>.

Contacts:

Mr. K Subharaman	Mr. Rakesh Parikh	Mr. M Gundu Rao
Tel: +912266888404	Tel: +912266888414	Tel: +912266888380
Cell: +919833031121	Cell: +919892925555	Cell: +919820228944
e-Mail: subharamank@unichemlabs.com	rparikh@unichemlabs.com	gundurao@unichemlabs.com



This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.